Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Bristol-Myers Squibb reports phase I data for the antithrombotic milvexian

Sep. 2, 2020

First clinical data for TAFIa inhibitor S-62798 presented

Sep. 2, 2020

FDA clears IND for clinical development of OMS-906 for PNH

Sep. 1, 2020

Discovery of novel HIF-PHD2 inhibitors for the treatment of anemia

Sep. 1, 2020

Early clinical reports suggest utility of Aggrastat for COVID-19-related thrombotic complications

Aug. 25, 2020

BioMarin receives complete response letter from FDA for valoctocogene roxaparvovec

Aug. 20, 2020

PRC member affects blood formation during aging

Aug. 10, 2020

Keros completes dosing of planned cohorts in phase I study of KER-047

Aug. 6, 2020

Novel humanized platelet mouse model predicts efficacy of experimental antiplatelet drugs

Aug. 5, 2020

Data presented for factor XIa inhibitor milvexian in thrombosis models

Aug. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...